RCM
DSGN icon

RA Capital Management’s Design Therapeutics DSGN Stock Holding History

RA Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.6M Buy
2,972,973
+1,511,592
+103% +$15.3M 0.34% 44
2025
Q4 		$13.7M Buy
1,461,381
+985,682
+207% +$7.72M 0.14% 56
2025
Q3 		$3.58M Buy
+475,699
New +$2.38M 0.04% 64
2023
Q3 		– Sell
-2,971,231
Closed -$18.7M – 67
2023
Q2 		$18.7M Hold
2,971,231
– – 0.35% 45
2023
Q1 		$17.1M Hold
2,971,231
– – 0.39% 48
2022
Q4 		$30.5M Buy
2,971,231
+198,000
+7% +$2.68M 0.62% 40
2022
Q3 		$46.4M Buy
2,773,231
+586,595
+27% +$11.7M 0.99% 34
2022
Q2 		$30.6M Hold
2,186,636
– – 0.82% 36
2022
Q1 		$35.3M Hold
2,186,636
– – 0.77% 41
2021
Q4 		$46.8M Hold
2,186,636
– – 0.83% 35
2021
Q3 		$32.1M Hold
2,186,636
– – 0.45% 50
2021
Q2 		$43.5M Hold
2,186,636
– – 0.7% 47
2021
Q1 		$65.4M Buy
+2,186,636
New +$73.8M 0.99% 33

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

RA Capital Management's DSGN Position: Q1 2026 in Review

RA Capital Management increased its Design Therapeutics (DSGN) stake by 103% in Q1 2026, buying an estimated $15.3M and bringing the position to 2,972,973 shares worth $31.6M. The position accounts for 0.34% of the portfolio, ranked #44.

RA Capital Management first reported a position in DSGN in Q1 2021 and has held it in 13 quarters since. The position peaked at $65.4M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • RA Capital Management held 2,972,973 shares of Design Therapeutics worth $31.6M as of Q1 2026.
  • RA Capital Management bought 1,511,592 Design Therapeutics shares in Q1 2026, an estimated $15.3M.
  • Design Therapeutics made up 0.34% of RA Capital Management's portfolio in Q1 2026, its #44 holding.
  • RA Capital Management first reported a position in Design Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • RA Capital Management's Design Therapeutics position peaked at $65.4M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.